---
document_datetime: 2025-06-03 14:33:57
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imcivree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imcivree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.690196
conversion_datetime: 2025-12-28 05:10:35.238437
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IMCIVREE

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| II/0034              | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 03/04/2025                          |                                             | SmPC and PL                      |                                   |
| PSUSA/10941 /202405  | Periodic Safety Update EU Single assessment - setmelanotide                                                       | 16/01/2025                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0033             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   | 10/12/2024   | n/a        |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IB/0032             | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                        | 10/12/2024   | n/a        |                        |                                   |
| IB/0029             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                         | 10/09/2024   | n/a        |                        |                                   |
| IB/0028             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                     | 26/08/2024   | n/a        |                        |                                   |
| IB/0027             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                     | 29/07/2024   | n/a        |                        |                                   |
| II/0018             | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                 | 27/06/2024   | 26/07/2024 | SmPC and PL            |                                   |
| PSUSA/10941 /202311 | Periodic Safety Update EU Single assessment - setmelanotide                                                                                                                                                    | 13/06/2024   | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0022             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                     | 14/05/2024   | 26/07/2024 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| IA/0025     | - Change in test procedure for AS or material/reagent/intermediate - Minor to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                      | 29/04/2024   | n/a        |                 | B.I.b.2.a starting changes   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|------------------------------|
| IB/0024     | B.I.a.3.z - Change in batch size (including batch size ranges) of AS or intermediate - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/04/2024   | n/a        |                 |                              |
| IA/0023     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                              | 15/03/2024   | n/a        |                 |                              |
| IAIN/0020/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - control/testing | 04/03/2024   | 26/07/2024 | Annex II and PL | Not including batch          |
| IA/0021     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                           | 29/02/2024   | n/a        |                 |                              |

<div style=\"page-break-after: always\"></div>

| PSUSA/10941 /202305   | Periodic Safety Update EU Single assessment - setmelanotide                                                                                                                                                                                                                                                                                                                            | 11/01/2024   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                      |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017               | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                   | 05/12/2023   | n/a        |                        |                                                                                                                                                                                                                        |
| II/0015               | Submission of the final report from study RM-493- 014. This is a phase 2 treatment trial of setmelanotide in patients with rare genetic disorders of obesity. The requested variation proposed no amendments to the Product Information. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 26/10/2023   | n/a        |                        |                                                                                                                                                                                                                        |
| PSUSA/10941 /202211   | Periodic Safety Update EU Single assessment - setmelanotide                                                                                                                                                                                                                                                                                                                            | 08/06/2023   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                      |
| IB/0013               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                              | 18/03/2023   | 22/09/2023 | SmPC                   | Product information section 6.3 is updated to reflect the shelf-life extension of the finished product Imcivree 10 mg/ml solution for injection (EU/1/21/1564/0001-0002) as packaged for sale from 2 years to 3 years. |
| PSUSA/10941 /202205   | Periodic Safety Update EU Single assessment - setmelanotide                                                                                                                                                                                                                                                                                                                            | 12/01/2023   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                      |
| IB/0012               | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside                                                                                                                                                                                                                                   | 31/10/2022   | 22/09/2023 | SmPC, Labelling and PL |                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             |                                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------|
| II/0002/G | This was an application for a group of variations. To add the new therapeutic indication for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC and sections 1, 3 and 4 of the PL are updated accordingly. The updated RMP version 1.0 has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 21/07/2022 | 02/09/2022 | SmPC and PL | Please refer to Scientific Discussion 'Imcivree-H-C-005089- II-02-G' |
| IB/0010   | B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 28/07/2022 | n/a        |             |                                                                      |
| IB/0008   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 30/06/2022 | n/a        |             |                                                                      |
| IA/0009   | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/06/2022 | n/a        |             |                                                                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/10941 /202111   | Periodic Safety Update EU Single assessment - setmelanotide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/06/2022   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                          |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003               | Update of sections 4.2, and 5.2 of the SmPC in order to change posology recommendations in patients with renal impairment, based on final results from study RM-493-029, a Phase I, open-label, single- dose study to evaluate the pharmacokinetics of setmelanotide in subjects with varying degrees of renal impairment; with secondary objectives to evaluate the safety and tolerability of a single dose of setmelanotide administered subcutaneously in subjects with varying degrees of renal impairment. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 22/04/2022   | 02/06/2022 | SmPC and PL | Based on the submitted data and clinical considerations, new dosing recommendations (including information on dose titration with lowest starting dose and maximum dose) for patients with severe renal impairment have been added. No dosage adjustment is necessary for patients with mild or moderate renal impairment. |
| II/0006               | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 12/05/2022   | n/a        |             |                                                                                                                                                                                                                                                                                                                            |
| II/0005/G             | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting                                                                                                                                                                                                                                                                                                                                                                             | 12/05/2022   | n/a        |             |                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Change outside the approved specifications limits range for the AS   |            |            |                        |
|-----------|------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IAIN/0007 | A.1 - Administrative change - Change in the name and/or address of the MAH                           | 30/03/2022 | 02/06/2022 | SmPC, Labelling and PL |
| T/0001    | Transfer of Marketing Authorisation                                                                  | 24/09/2021 | 22/10/2021 | SmPC, Labelling and PL |